CTOs on the Move

PTC Therapeutics

www.ptcbio.com

 
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC`s ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.ptcbio.com
  • 100 Corporate Court
    South Plainfield, NJ USA 07080
  • Phone: 908.222.7000

Executives

Name Title Contact Details
Giovanni Sosa
Director Security Architect Profile
Marcio Souza
Chief Operating Officer Profile
Benjamin Zaborenko
Senior Director, IT Security Profile

Funding

PTC Therapeutics raised $125M on 08/12/2015

Similar Companies

Elevation Oncology

Elevation Oncology is founded on the belief that every patient living with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. We aim to make genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of tumor growth. Together with our peers, we work towards a future in which each tumor`s unique genomic test result can be matched with a purpose-built precision medicine to enable an individualized treatment plan for each patient. Our lead candidate, seribantumab, is intended to inhibit tumor growth driven by NRG1 fusions and is currently being evaluated in the Phase 2 CRESTONE study for patients with solid tumors of any origin that have an NRG1 gene fusion.

Crown Bioscience

Crown bioscience is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioTime

BioTime is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. BioTime`s pipeline is based on two platform technologies which encompass cell replacement and cell/drug delivery. BioTime`s lead cell replacement product candidate is OpRegen®, a retinal pigment epithelium transplant therapy in Phase 2 development for the treatment of dry age-related macular degeneration, the leading cause of blindness in the developed world. BioTime common stock is traded on the NYSE American and TASE under the symbol BTX.

Allyis Inc

Allyis Inc is a Bellevue, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CINDE Journal

CINDE Journal is a Hamilton, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.